tradingkey.logo

Niagen Bioscience Inc

NAGE
View Detailed Chart
6.510USD
-0.200-2.98%
Close 12/23, 16:00ETQuotes delayed by 15 min
518.45MMarket Cap
24.82P/E TTM

Niagen Bioscience Inc

6.510
-0.200-2.98%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.98%

5 Days

+2.68%

1 Month

-5.38%

6 Months

-51.56%

Year to Date

+22.71%

1 Year

+22.83%

View Detailed Chart

Key Insights

Niagen Bioscience Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 45/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.80.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Niagen Bioscience Inc's Score

Industry at a Glance

Industry Ranking
45 / 404
Overall Ranking
140 / 4578
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
15.800
Target Price
+143.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Niagen Bioscience Inc Highlights

StrengthsRisks
Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.23% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 99.60M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 25.58, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 29.97M shares, increasing 2.62% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 5.11K shares of this stock.

Niagen Bioscience Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Niagen Bioscience Inc Info

Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Ticker SymbolNAGE
CompanyNiagen Bioscience Inc
CEOFried (Robert N)
Websitehttps://www.niagenbioscience.com/

FAQs

What is the current price of Niagen Bioscience Inc (NAGE)?

The current price of Niagen Bioscience Inc (NAGE) is 6.510.

What is the symbol of Niagen Bioscience Inc?

The ticker symbol of Niagen Bioscience Inc is NAGE.

What is the 52-week high of Niagen Bioscience Inc?

The 52-week high of Niagen Bioscience Inc is 14.690.

What is the 52-week low of Niagen Bioscience Inc?

The 52-week low of Niagen Bioscience Inc is 5.160.

What is the market capitalization of Niagen Bioscience Inc?

The market capitalization of Niagen Bioscience Inc is 518.45M.

What is the net income of Niagen Bioscience Inc?

The net income of Niagen Bioscience Inc is 8.55M.

Is Niagen Bioscience Inc (NAGE) currently rated as Buy, Hold, or Sell?

According to analysts, Niagen Bioscience Inc (NAGE) has an overall rating of Buy, with a price target of 15.800.

What is the Earnings Per Share (EPS TTM) of Niagen Bioscience Inc (NAGE)?

The Earnings Per Share (EPS TTM) of Niagen Bioscience Inc (NAGE) is 0.262.
KeyAI